Manhattan Pharmaceuticals to start phase 2a anti-obesity trial

By Elaine Rigoli

Tampa, Fla., May 16 - Manhattan Pharmaceuticals, Inc. has received Swiss regulatory approval to start its phase 2a study with oral oleoyl-estrone, the company's drug candidate for the treatment of obesity.

Oleoyl-estrone is an orally administered, synthetic form of oleoyl-estrone, a molecule that exists naturally in the body.

The single center, phase 2a study is a randomized, double-blind, placebo-controlled, parallel group study designed to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day dosing cycles in obese adult subjects, according to a news release.

Subjects in the phase 1b study experienced weight loss as well as beneficial changes in blood glucose and cholesterol level, the release said. There was also evidence of oleoyl-estrone offering the potential for sustained weight loss after dosing with oleoyl-estrone stopped.

Manhattan Pharmaceuticals is a development-stage pharmaceutical company located in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.